Evaluation of Two Beta-Tricalcium Phosphates with Different Particle Dimensions in Human Maxillary Sinus Floor Elevation: A Prospective, Randomized Clinical Trial

This study aimed to compare two beta-tricalcium phosphates with different particle sizes in human maxillary sinuses lifting. The immunolabeling of cells for RUNX2 and VEGF were performed to evaluate the osteoblast precursor cells and the vascular formation after 6 months of bone repair. Ten maxillar...

ver descrição completa

Detalhes bibliográficos
Autores: Mendes, Bruno Coelho [UNESP], Pereira, Rodrigo Dos Santos, Mourão, Carlos Fernando de Almeida Barros, Montemezzi, Pietro, Santos, Anderson Maikon de Souza [UNESP], Moreno, Jéssica Monique Lopes [UNESP], Okamoto, Roberta [UNESP], Hochuli-Vieira, Eduardo [UNESP]
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:Brasil
Recursos:Universidade Estadual Paulista (UNESP)
Repositorio:Repositório Institucional da UNESP
Idioma:inglés
OAI Identifier:oai:repositorio.unesp.br:11449/230513
Acesso em linha:http://dx.doi.org/10.3390/ma15051824
http://hdl.handle.net/11449/230513
Access Level:acceso abierto
Palavra-chave:Biomaterials
Bone substitutes
Sinus floor augmentation
Descrição
Resumo:This study aimed to compare two beta-tricalcium phosphates with different particle sizes in human maxillary sinuses lifting. The immunolabeling of cells for RUNX2 and VEGF were performed to evaluate the osteoblast precursor cells and the vascular formation after 6 months of bone repair. Ten maxillary sinuses were grafted with autogenous bone graft (Group 1), 10 were grafted with ChronOs® (Group 2), and 10 were grafted with BETA-TCP® (Group 3). After 6 months of bone healing, biopsies were obtained to assess the new bone formed by histomorphometric and immunohistochemical evaluation for RUNX2 and VEGF. The mean bone formation for Group 1 was 51.4 ± 17.4%. Group 2 presented 45.5 ± 9.9%, and Group 3 conferred 35.4 ± 8.0% of new bone formation. The RUNX2 offered low for Groups 1 and 2 with high cellular activity for osteoblast in Group 3. The VEGF immunolabeling was moderate for Groups 1 and 2 and intense for Group 3. In conclusion, it was possible to show that the bone substitutes evaluated in the present study presented suitable outcomes for bone regeneration, being an alternative for the autogenous bone graft in maxillary sinus bone height reconstruction.